Sep 07, 2023 / 12:50PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
So delighted to introduce our next speakers from GSK, Phil Dormitzer. Phil is Senior Vice President, Head of Vaccines Research and Development. I got that more or less correct?
Phil Dormitzer - GSK plc - Global Head of Vaccines R&D
Yes.
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
Excellent. I've also got Jeff McLaughlin from GSK IR. So thank you for joining us today.
Unsurprisingly, and Phil will be reassured, this conversation is going to be about vaccines. It would be a surprise if there was anything else. Obviously, from a commercial point of view, GSK is in a very important point because you're just launching Arexvy now. And Shingrix has obviously been a great success. You've got supply ongoing.
GSK plc at Citi BioPharma Conference Transcript
Sep 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers